A Phase 2, Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants
Latest Information Update: 07 Apr 2025
At a glance
- Drugs Pneumococcal 20-valent conjugate vaccine (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
- 02 Apr 2025 Number of treatment arms were increased from 6 to 8 by the addition of Experimental: Group 4 PG4 and Active Comparator: Group 4 15-valent pneumococcal conjugate vaccine (PCV15).
- 02 Apr 2025 Planned number of patients changed from 500 to 800.
- 02 Apr 2025 Planned End Date changed from 4 Aug 2026 to 27 May 2027.